Amanta Healthcare IPO Listing: Amanta Healthcare share price made a strong debut in the Indian stock market today. The stock was on Tuesday at ₹135 apiece on NSE, a premium of 7.14 percent to its issue price of ₹126 per share. Meanwhile, on BSE, it listed at Ed 134, up 6.35 percent from issue price.
Amanta Healthcare IPO listing was same as the Street expectations as indicated by the grey market premium (). Amanta Healthcare IPO GMP today was ₹9 per share. This indicated listing at ₹135, a premium of 7.14 percent.
About Amanta Healthcare IPO
Amanta Healthcare IPO, which opened for public subscription on September 1 and closed on September 3, successfully listed on both BSE and NSE on September 9. The allotment was finalized on September 4, enabling a smooth market debut for investors.
Amanta Healthcare successfully mobilised ₹126 crore through its book-built public issue, which consisted entirely of a fresh issue of 1 crore equity shares. For retail investors, the lot size was set at 119 shares, translating to a minimum investment commitment of ₹14,994.
The IPO saw overwhelming investor participation, with BSE data showing an overall of 82.61 times. The retail quota was subscribed 54.98 times, indicating robust retail interest. Non-Institutional Investors (NIIs) led the momentum with a remarkable 209.42 times subscription, while Qualified Institutional Buyers (QIBs) subscribed 35.86 times, reflecting broad-based demand across categories.
The proceeds from the IPO will primarily fund capital expenditure for civil construction and the procurement of equipment, plant, and machinery to set up a new SteriPort manufacturing line at Hariyala, Kheda, Gujarat. Funds will also support the development of a new SVP manufacturing line at the same facility and meet general corporate requirements.
Beeline Capital Advisors Pvt. Ltd. acted as the book-running lead manager, and MUFG Intime India Pvt. Ltd. handled registrar responsibilities.
About Amanta Healthcare
Established in December 1994, Amanta Healthcare Limited is a leading pharmaceutical company specialising in sterile liquid products. Its expertise lies in the development, manufacturing, and marketing of parenteral solutions, which are packaged using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies.
The company’s product portfolio includes IV fluids, diluents, ophthalmic solutions, and respiratory care products. It also produces irrigation solutions, first-aid essentials, and eye lubricants under its medical device division, strengthening its presence in the healthcare segment.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.